Chow, Christine
https://orcid.org/0000-0001-5098-5731
Mayo Clinic
Genetic Pathology Evaluation Center Vancouver BC Canada
Citations 2
The proteome of clear cell ovarian carcinoma
Ji, Jennifer X. , Cochrane, Dawn R. , Negri, Gian Luca , Colborne, Shane, Hoang, Lynn , Tessier‐Cloutier, Basile , Huvila, Jutta , Thompson, Emily F. , Leung, Samuel , Chow, Christine , Ta, Monica , Köbel, Martin , Feil, Lucas, Anglesio, Michael S. , Goode, Ellen L. , Huntsman, David G. , Tessier-Cloutier, Basile , Huvila, Jutta , Thompson, Emily , Anglesio, Michael S , Huntsman, David G , Köbel, Martin , Miko, Sandra E. Spencer , Farnell, David , Chiu, Derek S , Bolton, Kelly L. , Morin, Gregg B.
The Journal of Pathology | August 29, 2022 | Volume: 258 | Issue: 4 | Pages: 325-338
AbstractClear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late‐stage CCOC is not responsive to gold‐standard chemotherapy and results in suboptimal outcomes for patients. In‐depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. © 2022 The Pathological Society of Great Britain and Ireland.
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Rambau, Peter , Vierkant, Robert A. , Intermaggio, Maria P., Kelemen, Linda E. , Goodman, Marc T. , Herpel, Esther , Kommoss, Stefan , Jimenez‐Liñan, Mercedes , Menon, Usha , Polo, Susanna Hernando, Reis, Francisco José Cândido dos , Gayther, Simon A. , Sharma, Raghwa , Harnett, Paul R. , Hatfield, Emma, Andrade, Jurandyr Moreira de , Nelson, Gregg , Steed, Helen , Schildkraut, Joellen M. , Carney, Micheal E, Høgdall, Estrid , Whittemore, Alice S. , Widschwendter, Martin , Kennedy, Catherine J. , Armasu, Sebastian M. , Daley, Frances , Coulson, Penny , Jones, Michael E. , Anglesio, Michael S. , Chow, Christine , Fazio, Anna de , García‐Closas, Montserrat , Huzarski, Tomasz , Jensen, Allan , Lubiński, Jan , Oszurek, Oleg, Benı́tez, Javier , Mina, Fady , Staebler, Annette , Taran, Florin‐Andrei , Pasternak, J , Talhouk, Aline , Rossing, Mary Anne, Hendley, Joy , Group, AOCS, Fereday, Sián , Ness, Roberta B., Sieh, Weiva , El‐Bahrawy, Mona , Lester, Jenny , Sinn, Hans‐Peter , Fasching, Peter A. , Chang‐Claude, Jenny , Moysich, Kirsten B. , Bowtell, David D.L. , Luk, Hugh, Shah, Mitul , Jung, Audrey , Alsop, Jennifer , Thompson, Pamela J., Swerdlow, Anthony J. , Karpinskyj, Chloe , García, María J. , Deen, Susha, Palacios, José , Koziak, Jennifer M. , Goode, Ellen L. , Huntsman, David G. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Köbel, Martin , Ramus, Susan J , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Swerdlow, Anthony J , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Anglesio, Michael S , Jones, Michael E , Sieh, Weiva , García-Closas, Montserrat , Benitez, Javier , Høgdall, Estrid , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Fereday, Sian , Lubinski, Jan , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Steed, Helen , Goodman, Marc T , Pharoah, Paul D.P. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Doherty, Jennifer A. , Larson, Melissa C. , Hatfield, Emma, Wang, Frances M. , Wang, Qin , Wang, Chen , Brucker, Sara Yvonne , Cybulski, Cezary , Harris, Holly R. , Hartkopf, Andreas D , Group, AOCS, Edwards, Todd , Modugno, Francesmary , Winham, Stacey J. , Kjær, Susanne K. , Gronwald, Jacek , Hernandez, Brenda Y. , Behrens, Sabine , Ghatage, Prafull , Alsop, Kathryn , García-Donás, Jesús , Cazorla, Alicia , Wilkens, Lynne R. , Berchuck, Andrew , Brenton, James D. , Cook, Linda S.
The Journal of Pathology: Clinical Research | July 30, 2018 | Volume: 4 | Issue: 4 | Pages: 250-261
AbstractWe aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.